Siglec receptors as new immune checkpoints in cancer
Molecular Aspects of Medicine, ISSN: 0098-2997, Vol: 90, Page: 101112
2023
- 55Citations
- 66Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations55
- Citation Indexes55
- 55
- CrossRef22
- Captures66
- Readers66
- 66
- Mentions1
- News Mentions1
- 1
Most Recent News
Carbon nanotubes activate inflammatory signalling through binding to Siglec-14 – Nature Nanotechnology
Dong, J. & Ma, Q. Nanotoxicol. 13 , 1244–1274 (2019). Article CAS Google Scholar Wang, S., Ma, J., Guo, S., Huang, Y.
Review Description
Cancer immunotherapy in the form of immune checkpoint inhibitors and cellular therapies has improved the treatment and prognosis of many patients. Nevertheless, most cancers are still resistant to currently approved cancer immunotherapies. New approaches and rational combinations are needed to overcome these resistances. There is emerging evidence that Siglec receptors could be regarded as new immune checkpoints and targets for cancer immunotherapy. In this review, we summarize the experimental evidence supporting Siglec receptors as new immune checkpoints in cancer and discuss their mechanisms of action, as well as current efforts to target Siglec receptors and their interactions with sialoglycan Siglec-ligands.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0098299722000577; http://dx.doi.org/10.1016/j.mam.2022.101112; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85135571913&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/35948467; https://linkinghub.elsevier.com/retrieve/pii/S0098299722000577; https://dx.doi.org/10.1016/j.mam.2022.101112
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know